Retinopathy and nephropathy in patients with type I diabetes four years after a trial of intensive therapy

New England Journal of Medicine

Volumn 342, Issue 6, 2000, Pages 381-389

  Lachin, John M ^a   Genuth, Saul ^a   Cleary, Patricia ^a   Davis, Matthew D ^a   Nathan, David M ^a  

^a Box NDIC/EDIC ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; INSULIN; MALE; RANDOMIZED CONTROLLED TRIALS; REGRESSION ANALYSIS; RISK; SEVERITY OF ILLNESS INDEX;

EID: 0034628425     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200002103420603     Document Type: Article

References (20)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive therapy of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
2. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Epidemiology of Diabetes Interventions and Complications (EDIC): design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 1999;22:99-111.
3. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 1991;98:Suppl:823-33.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol 1995;113:36-51.
5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-806.
6. Early Therapy Diabetic Retinopathy Study (ETDRS) manual of operations. Springfield, Va.: National Technical Information Service, 1985. (NTIS accession no. PB-85223006.)
7. Molitch ME, Steffers MW, Cleary PA, Nathan DM. Baseline analysis of renal function in the Diabetes Control and Complications Trial. Kidney Int 1993;43:668-74. [Erratum, Kidney Int 1993;43:1196.]
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
9. The DCCT Research Group. Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 1987;33:2267-71.
10. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames: Iowa State University Press, 1980.
11. Agresti A. Categorical data analysis. New York: John Wiley, 1990:80-91, 235-6.
12. Odell PM, Anderson KM, D'Agostino RB. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics 1992;48:951-9.
13. SAS/STAT user's guide, version 6. 4th ed. Cary, N.C.: SAS Institute, 1989.
14. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbAlc) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995;44:968-83.
15. Idem. Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998;116:874-86. [Erratum, Arch Ophthalmol 1998;116:1469.]
16. Reichard P. Are there any glycemic thresholds for the serious microvascular complications? J Diabetes Complications 1995;9:25-30.
17. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycemic control. Diabetes 1987;36-.808-12.
18. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced gly cosylation: biochemical, biological, and clinical implications for diabetes and aging. Lab Invest 1994;70:138-51.
19. Monnier VM, Bautista O, Kenny D, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbAlc as markers of diabetic complications. Diabetes 1999;48:870-80
20. The Diabetes Control and Complications Trial Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996;45:1289-98.